Advertisement
Journal of Investigative Dermatology Home

Propranolol Is an Effective Topical and Systemic Treatment Option for Experimental Epidermolysis Bullosa Acquisita

      Propranolol is an ADRB2 blocker that regulates heart muscle contractions, smooth muscle relaxation, and glycogenolysis. In addition, an increasing number of applications in dermatology have been described, most prominently, the use as a first-line treatment for infantile hemangiomas. We here show that propranolol enhances IL-8–induced neutrophil chemotaxis and reduces the release of ROS after immune complex stimulation. To obtain further molecular insights into the modulatory effects of propranolol in activated neutrophils, we performed RNA sequencing of immune complex–stimulated neutrophils in the absence and presence of the drug. We identified the transcriptomic signature of propranolol and demonstrated an ADR2-independent immunomodulatory effect. To determine if the anti-inflammatory transcriptomic signature of propranolol also translates into clinical effects, we next evaluated the impact of propranolol in a prototypical neutrophil-dependent skin disease, specifically, antibody transfer–induced epidermolysis bullosa acquisita in mice. To validate the identified propranolol gene signature obtained in human neutrophils, we analyzed a selection of genes by RT-PCR in mouse epidermolysis bullosa acquisita skin and confirmed TNF, among others, to be differentially regulated by propranolol treatment. Our data clearly indicate that, based on its molecular impact on immune complex–activated neutrophils, propranolol is a potential treatment option for neutrophil-mediated inflammatory skin diseases.

      Abbreviations:

      ADR (adrenoreceptor), EBA (epidermolysis bullosa acquisita), IC (immune complex), IH (infantile hemangioma), PD (pemphigoid disease), PMN (polymorphonuclear), RNA-Seq (RNA sequencing)
      To read this article in full you will need to make a payment
      Purchase one-time access
      Society Members (SID/ESDR), remember to log in for access.
      Subscribe to Journal of Investigative Dermatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Akiyama M.
        • Takeichi T.
        • McGrath J.A.
        • Sugiura K.
        Autoinflammatory keratinization diseases: an emerging concept encompassing various inflammatory keratinization disorders of the skin.
        J Dermatol Sci. 2018; 90: 105-111
        • Anderson R.
        • Ramafi G.
        • Theron A.J.
        Membrane stabilizing, anti-oxidative interactions of propranolol and dexpropranolol with neutrophils.
        Biochem Pharmacol. 1996; 52: 341-349
        • Anderson R.
        • van Rensburg A.J.
        The in vitro effects of propranolol and atenolol on neutrophil motility and post-phagocytic metabolic activity.
        Immunology. 1979; 37: 15-24
        • Bech R.
        • Kibsgaard L.
        • Vestergaard C.
        Comorbidities and treatment strategies in bullous pemphigoid: an appraisal of the existing litterature.
        Front Med (Lausanne). 2018; 5: 238
        • Bieber K.
        • Koga H.
        • Nishie W.
        In vitro and in vivo models to investigate the pathomechanisms and novel treatments for pemphigoid diseases.
        Exp Dermatol. 2017; 26: 1163-1170
        • Bieber K.
        • Sun S.
        • Witte M.
        • Kasprick A.
        • Beltsiou F.
        • Behnen M.
        • et al.
        Regulatory T cells suppress inflammation and blistering in pemphigoid diseases.
        Front Immunol. 2017; 8: 1628
        • Bieber K.
        • Witte M.
        • Sun S.
        • Hundt J.E.
        • Kalies K.
        • Dräger S.
        • et al.
        T cells mediate autoantibody-induced cutaneous inflammation and blistering in epidermolysis bullosa acquisita.
        Sci Rep. 2016; 6: 38357
        • Bozic C.R.
        • Gerard N.P.
        • von Uexkull-Guldenband C.
        • Kolakowski Jr., L.F.
        • Conklyn M.J.
        • Breslow R.
        • et al.
        The murine interleukin 8 type B receptor homologue and its ligands. Expression and biological characterization.
        J Biol Chem. 1994; 269: 29355-29358
        • Chen Y.W.
        • Chiu C.C.
        • Wei Y.L.
        • Hung C.H.
        • Wang J.J.
        Propranolol combined with dopamine has a synergistic action in intensifying and prolonging cutaneous analgesia in rats.
        Pharmacol Rep. 2015; 67: 1224-1229
        • Chiriac M.T.
        • Roesler J.
        • Sindrilaru A.
        • Scharffetter-Kochanek K.
        • Zillikens D.
        • Sitaru C.
        NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage.
        J Pathol. 2007; 212: 56-65
        • Coxon A.
        • Cullere X.
        • Knight S.
        • Sethi S.
        • Wakelin M.W.
        • Stavrakis G.
        • et al.
        Fc gamma RIII mediates neutrophil recruitment to immune complexes. A mechanism for neutrophil accumulation in immune-mediated inflammation.
        Immunity. 2001; 14: 693-704
        • De Giorgi V.
        • Grazzini M.
        • Benemei S.
        • Marchionni N.
        • Botteri E.
        • Pennacchioli E.
        • et al.
        Propranolol for off-label treatment of patients with melanoma: results from a cohort study.
        JAMA Oncol. 2018; 4e172908
        • Dobin A.
        • Davis C.A.
        • Schlesinger F.
        • Drenkow J.
        • Zaleski C.
        • Jha S.
        • et al.
        STAR: ultrafast universal RNA-seq aligner.
        Bioinformatics. 2013; 29: 15-21
        • Drolet B.A.
        • Frommelt P.C.
        • Chamlin S.L.
        • Haggstrom A.
        • Bauman N.M.
        • Chiu Y.E.
        • et al.
        Initiation and use of propranolol for infantile hemangioma: report of a consensus conference.
        Pediatrics. 2013; 131: 128-140
        • El Hachem M.
        • Gesualdo F.
        • Diociaiuti A.
        • Berti I.
        • Vercellino N.
        • Boccaletti V.
        • et al.
        Safety and effectiveness of oral propranolol for infantile hemangiomas started before 5 weeks and after 5 months of age: an Italian multicenter experience.
        Ital J Pediatr. 2017; 43: 40
        • English D.
        • Taylor G.S.
        Divergent effects of propranolol on neutrophil superoxide release: involvement of phosphatidic acid and diacylglycerol as second messengers.
        Biochem Biophys Res Commun. 1991; 175: 423-429
        • Frolov V.A.
        • Moiseeva E.G.
        • Pasechnik A.V.
        Pathophysiological aspects of functional modulation of human peripheral blood neutrophils with propranolol.
        Bull Exp Biol Med. 2006; 141: 675-677
        • Grando S.A.
        • Glukhenky B.T.
        • Drannik G.N.
        • Epshtein E.V.
        • Kostromin A.P.
        • Korostash T.A.
        Mediators of inflammation in blister fluids from patients with pemphigus vulgaris and bullous pemphigoid.
        Arch Dermatol. 1989; 125: 925-930
        • Gurung P.
        • Kanneganti T.D.
        Autoinflammatory skin disorders: the inflammasomme in focus.
        Trends Mol Med. 2016; 22: 545-564
        • Hirose M.
        • Brandolini L.
        • Zimmer D.
        • Götz J.
        • Westermann J.
        • Allegretti M.
        • et al.
        The allosteric CXCR1/2 inhibitor DF2156A improves experimental epidermolysis bullosa acquisita.
        Genet Syndr Gene Ther. 2013; S3: 1-9
        • Hirose M.
        • Kasprick A.
        • Beltsiou F.
        • Dieckhoff Schulze K.
        • Schulze F.S.
        • Samavedam U.K.
        • et al.
        Reduced skin blistering in experimental epidermolysis bullosa acquisita after anti-TNF treatment.
        Mol Med. 2017; 22: 918-926
        • Hübner F.
        • Recke A.
        • Zillikens D.
        • Linder R.
        • Schmidt E.
        Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany.
        J Invest Dermatol. 2016; 136: 2495-2498
        • Ivetic A.
        A head-to-tail view of L-selectin and its impact on neutrophil behaviour.
        Cell Tissue Res. 2018; 371: 437-453
        • Iwata H.
        • Vorobyev A.
        • Koga H.
        • Recke A.
        • Zillikens D.
        • Prost-Squarcioni C.
        • et al.
        Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients.
        Orphanet J Rare Dis. 2018; 13: 153
        • Jean Wrobel L.
        • Bod L.
        • Lengagne R.
        • Kato M.
        • Prévost-Blondel A.
        • Le Gal F.A.
        Propranolol induces a favourable shift of anti-tumor immunity in a murine spontaneous model of melanoma.
        Oncotarget. 2016; 7: 77825-77837
        • Joly P.
        • Roujeau J.C.
        • Benichou J.
        • Picard C.
        • Dreno B.
        • Delaporte E.
        • et al.
        A comparison of oral and topical corticosteroids in patients with bullous pemphigoid.
        N Engl J Med. 2002; 346: 321-327
        • Karp N.A.
        • Mason J.
        • Beaudet A.L.
        • Benjamini Y.
        • Bower L.
        • Braun R.E.
        • et al.
        Prevalence of sexual dimorphism in mammalian phenotypic traits.
        Nat Commun. 2017; 8: 15475
        • Kasprick A.
        • Bieber K.
        • Ludwig R.J.
        Drug discovery for pemphigoid diseases.
        Curr Protoc Pharmacol. 2019; 84: e55
        • Kawana S.
        • Ueno A.
        • Nishiyama S.
        Increased levels of immunoreactive leukotriene B4 in blister fluids of bullous pemphigoid patients and effects of a selective 5-lipoxygenase inhibitor on experimental skin lesions.
        Acta Derm Venereol. 1990; 70: 281-285
        • Khan A.A.
        • Alsahli M.A.
        • Rahmani A.H.
        Myeloperoxidase as an active disease biomarker: recent biochemical and pathological perspectives.
        Med Sci (Basel). 2018; 6: 33
        • Killock D.
        Skin cancer: propranolol limits melanoma recurrence.
        Nat Rev Clin Oncol. 2017; 14: 714
        • Koga H.
        • Prost-Squarcioni C.
        • Iwata H.
        • Jonkman M.F.
        • Ludwig R.J.
        • Bieber K.
        Epidermolysis bullosa acquisita: the 2019 update.
        Front Med (Lausanne). 2019; 5: 362
        • Kovacs B.
        • Tillmann J.
        • Freund L.C.
        • Nimmerjahn F.
        • Sadik C.D.
        • Bieber K.
        • et al.
        Fcγ receptor IIB controls skin inflammation in an active model of epidermolysis bullosa acquisita.
        Front Immunol. 2020; 10: 3012
        • Kum J.J.
        • Khan Z.A.
        Mechanisms of propranolol action in infantile hemangioma.
        Dermatoendocrinol. 2015; 6e979699
        • Lamberts A.
        • Yale M.
        • Grando S.A.
        • Horváth B.
        • Zillikens D.
        • Jonkman M.F.
        Unmet needs in pemphigoid diseases: an international survey amongst patients, clinicians and researchers.
        Acta Derm Venereol. 2019; 99: 224-225
        • Léauté-Labrèze C.
        • Dumas de la Roque E.
        • Hubiche T.
        • Boralevi F.
        • Thambo J.B.
        • Taïeb A.
        Propranolol for severe hemangiomas of infancy.
        N Engl J Med. 2008; 358: 2649-2651
        • Léauté-Labrèze C.
        • Hoeger P.
        • Mazereeuw-Hautier J.
        • Guibaud L.
        • Baselga E.
        • Posiunas G.
        • et al.
        A randomized, controlled trial of oral propranolol in infantile hemangioma.
        N Engl J Med. 2015; 372: 735-746
        • Léauté-Labrèze C.
        • Voisard J.J.
        • Moore N.
        Oral propranolol for infantile hemangioma.
        N Engl J Med. 2015; 373: 284-285
        • Ludwig A.
        • Schiemann F.
        • Mentlein R.
        • Lindner B.
        • Brandt E.
        Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine.
        J Leukoc Biol. 2002; 72: 183-191
        • Ludwig R.J.
        • Vanhoorelbeke K.
        • Leypoldt F.
        • Kaya Z.
        • Bieber K.
        • McLachlan S.M.
        • et al.
        Mechanisms of autoantibody-induced pathology.
        Front Immunol. 2017; 8: 603
        • Luo Y.
        • Zeng Y.
        • Zhou B.
        • Tang J.
        A retrospective study of propranolol therapy in 635 infants with infantile hemangioma.
        Pediatr Dermatol. 2015; 32: 151-152
        • Marqueling A.L.
        • Oza V.
        • Frieden I.J.
        • Puttgen K.B.
        Propranolol and infantile hemangiomas four years later: a systematic review.
        Pediatr Dermatol. 2013; 30: 182-191
        • Mashiah J.
        • Kutz A.
        • Rabia S.H.
        • Ilan E.B.
        • Goldberg I.
        • Sprecher E.
        • et al.
        Assessment of the effectiveness of topical propranolol 4% gel for infantile hemangiomas.
        Int J Dermatol. 2017; 56: 148-153
        • Michel M.C.
        • Bond R.A.
        • Summers R.J.
        Adrenoceptors-new roles for old players.
        Br J Pharmacol. 2019; 176: 2339-2342
        • Nakazato T.
        • Sagawa M.
        • Yamato K.
        • Xian M.
        • Yamamoto T.
        • Suematsu M.
        • et al.
        Myeloperoxidase is a key regulator of oxidative stress mediated apoptosis in myeloid leukemic cells.
        Clin Cancer Res. 2007; 13: 5436-5445
        • Navarini A.A.
        • Satoh T.K.
        • French L.E.
        Neutrophilic dermatoses and autoinflammatory diseases with skin involvement--innate immune disorders.
        Semin Immunopathol. 2016; 38: 45-56
        • Neri I.
        • Baraldi C.
        • Balestri R.
        • Piraccini B.M.
        • Patrizi A.
        Topical 1% propranolol ointment with occlusion in treatment of pyogenic granulomas: an open-label study in 22 children.
        Pediatr Dermatol. 2018; 35: 117-120
        • Ng L.G.
        • Ostuni R.
        • Hidalgo A.
        Heterogeneity of neutrophils.
        Nat Rev Immunol. 2019; 19: 255-265
        • Oberlin K.E.
        Expanding uses of propranolol in dermatology.
        Cutis. 2017; 99: E17-E19
        • Pierson M.E.
        • Lyon R.A.
        • Titeler M.
        • Schulman S.B.
        • Kowalski P.
        • Glennon R.A.
        Design and synthesis of propranolol analogues as serotonergic agents.
        J Med Chem. 1989; 32: 859-863
        • Püttgen K.B.
        Evidence and nuances of propranolol safety.
        Br J Dermatol. 2015; 172: 319-320
        • Recke A.
        • Trog L.M.
        • Pas H.H.
        • Vorobyev A.
        • Abadpour A.
        • Jonkman M.F.
        • et al.
        Recombinant human IgA1 and IgA2 autoantibodies to type VII collagen induce subepidermal blistering ex vivo.
        J Immunol. 2014; 193: 1600-1608
        • Romana-Souza B.
        • Nascimento A.P.
        • Monte-Alto-Costa A.
        Low-dose propranolol improves cutaneous wound healing of burn-injured rats.
        Plast Reconstr Surg. 2008; 122: 1690-1699
        • Rosales C.
        Neutrophil: a cell with many roles in inflammation or several cell types?.
        Front Physiol. 2018; 9: 113
        • Rovai L.E.
        • Herschman H.R.
        • Smith J.B.
        The murine neutrophil-chemoattractant chemokines LIX, KC, and MIP-2 have distinct induction kinetics, tissue distributions, and tissue-specific sensitivities to glucocorticoid regulation in endotoxemia.
        J Leukoc Biol. 1998; 64: 494-502
        • Sadeghi H.
        • Gupta Y.
        • Möller S.
        • Samavedam U.K.
        • Behnen M.
        • Kasprick A.
        • et al.
        The retinoid-related orphan receptor alpha is essential for the end-stage effector phase of experimental epidermolysis bullosa acquisita.
        J Pathol. 2015; 237: 111-122
        • Sadeghi H.
        • Lockmann A.
        • Hund A.C.
        • Samavedam U.K.S.R.L.
        • Pipi E.
        • Vafia K.
        • et al.
        Caspase-1-independent IL-1 release mediates blister formation in autoantibody-induced tissue injury through modulation of endothelial adhesion molecules.
        J Immunol. 2015; 194: 3656-3663
        • Sagi L.
        • Zvulunov A.
        • Lapidoth M.
        • Ben Amitai D.
        Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases.
        Dermatology. 2014; 228: 136-144
        • Samavedam U.K.
        • Mitschker N.
        • Kasprick A.
        • Bieber K.
        • Schmidt E.
        • Laskay T.
        • et al.
        Whole-genome expression profiling in skin reveals SYK as a key regulator of inflammation in experimental epidermolysis bullosa acquisita.
        Front Immunol. 2018; 9: 249
        • Scanzano A.
        • Cosentino M.
        Adrenergic regulation of innate immunity: a review.
        Front Pharmacol. 2015; 6: 171
        • Schmidt E.
        • Ambach A.
        • Bastian B.
        • Bröcker E.B.
        • Zillikens D.
        Elevated levels of interleukin-8 in blister fluid of bullous pemphigoid compared with suction blisters of healthy control subjects.
        J Am Acad Dermatol. 1996; 34: 310-312
        • Schmidt E.
        • Reimer S.
        • Kruse N.
        • Bröcker E.B.
        • Zillikens D.
        The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone.
        Clin Exp Immunol. 2001; 124: 157-162
        • Schmidt E.
        • Zillikens D.
        The diagnosis and treatment of autoimmune blistering skin disorders.
        Dtsch Arztebl Int. 2011; 108 ([in German]): 399-405
        • Schmidt E.
        • Zillikens D.
        Pemphigoid diseases.
        Lancet. 2013; 381: 320-332
        • Sezin T.
        • Krajewski M.
        • Wutkowski A.
        • Mousavi S.
        • Chakievska L.
        • Bieber K.
        • et al.
        The leukotriene B4 and its receptor BLT1 act as critical drivers of neutrophil recruitment in murine bullous pemphigoid-like epidermolysis bullosa acquisita.
        J Invest Dermatol. 2017; 137: 1104-1113
        • Sitaru C.
        • Mihai S.
        • Otto C.
        • Chiriac M.T.
        • Hausser I.
        • Dotterweich B.
        • et al.
        Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen.
        J Clin Invest. 2005; 115: 870-878
        • Skoog W.A.
        • Beck W.S.
        Studies on the fibrinogen, dextran and phytohemagglutinin methods of isolating leukocytes.
        Blood. 1956; 11: 436-454
        • Soehnlein O.
        • Steffens S.
        • Hidalgo A.
        • Weber C.
        Neutrophils as protagonists and targets in chronic inflammation.
        Nat Rev Immunol. 2017; 17: 248-261
        • Sozzani S.
        • Agwu D.E.
        • McCall C.E.
        • O'Flaherty J.T.
        • Schmitt J.D.
        • Kent J.D.
        • et al.
        Propranolol, a phosphatidate phosphohydrolase inhibitor, also inhibits protein kinase C.
        J Biol Chem. 1992; 267: 20481-20488
        • Tiwari P.
        • Pandey V.
        • Gangopadhyay A.N.
        • Sharma S.P.
        • Gupta D.K.
        Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study.
        Oral Maxillofac Surg. 2016; 20: 73-77
        • Tukaj S.
        • Bieber K.
        • Kleszczyński K.
        • Witte M.
        • Cames R.
        • Kalies K.
        • et al.
        Topically applied Hsp90 Blocker 17AAG inhibits autoantibody-mediated blister-inducing cutaneous inflammation.
        J Invest Dermatol. 2017; 137: 341-349
        • Tukaj S.
        • Hellberg L.
        • Ueck C.
        • Hänsel M.
        • Samavedam U.
        • Zillikens D.
        • et al.
        Heat shock protein 90 is required for ex vivo neutrophil-driven autoantibody-induced tissue damage in experimental epidermolysis bullosa acquisita.
        Exp Dermatol. 2015; 24: 471-473
        • Van Dijk H.
        • Rapis M.
        • Jacobse-Geels H.E.
        • Willers J.M.
        Histamine 2 receptor-mediated immunomodulation in the mouse. I. Immunomodulation by the H2 agonist tolazoline.
        Clin Exp Immunol. 1979; 35: 470-477
        • Wang Y.
        • Zhang X.
        • Yang Y.
        • Zhang J.
        • Yang Y.
        • Lu Y.
        Efficacy and safety of 2% topical propranolol cream for the treatment of proliferating infantile strawberry hemangiomas.
        Indian J Pediatr. 2017; 84: 425-429
        • Witte M.
        • Koga H.
        • Hashimoto T.
        • Ludwig R.J.
        • Bieber K.
        Discovering potential drug-targets for personalized treatment of autoimmune disorders - what we learn from epidermolysis bullosa acquisita.
        Expert Opin Ther Targets. 2016; 20: 985-998
        • Wozel G.
        • Blasum C.
        • Winter C.
        • Gerlach B.
        Dapsone hydroxylamine inhibits the LTB4-induced chemotaxis of polymorphonuclear leukocytes into human skin: results of a pilot study.
        Inflamm Res. 1997; 46: 420-422
        • Wozel G.
        • Lehmann B.
        Dapsone inhibits the generation of 5-lipoxygenase products in human polymorphonuclear leukocytes.
        Skin Pharmacol. 1995; 8: 196-202
        • Xue L.
        • Sun C.
        • Xu D.P.
        • Liu Z.M.
        • Wang X.K.
        Clinical outcomes of infants with periorbital hemangiomas treated with oral propranolol.
        J Oral Maxillofac Surg. 2016; 74: 2193-2199
        • Zanela da Silva Marques T.
        • Santos-Oliveira R.
        • Betzler de Oliveira de Siqueira L.
        • Cardoso V.D.S.
        • de Freitas Z.M.F.
        • Barros R.C.D.S.A.
        • et al.
        Development and characterization of a nanoemulsion containing propranolol for topical delivery.
        Int J Nanomedicine. 2018; 13: 2827-2837